Rhythm Pharmaceuticals, Inc.’s Imcivree has shown strong efficacy in a Phase II hypothalamic obesity trial, helping expand its potential market far beyond obesity caused by rare genetic problems.
Imcivree (setmelanotide) is on the US market for patients aged six years or older with obesity due to deficiencies in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?